Images List Premium Download Classic

Immune Response

Immune Response-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Activation of innate immunity for enhanced nuclear reprogramming of somatic cells with mrna
The Board Of Trustees Of The Leland Stanford Junior University
July 20, 2017 - N°20170204376

The nuclear reprogramming of somatic cells with mrna encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of pkr, of toll-like receptors, e. G. Tlr3, etc. In some embodiments the mrna provides the activator of innate immunity.
Antagonistic peptides
Deakin University
July 20, 2017 - N°20170204140

The present invention relates to a compositions and methods for treating and/or preventing neurologic disorders such as alzheimer's disease and disorders associated with an increase of the th2 immune response such as allergic inflammation.
Vaccine delivery method
University Of Georgia Research Foundation, Inc.
July 20, 2017 - N°20170202958

The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological ph, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune response in a subject and vaccinating a subject by administering ...
Immune Response Patent Pack
Download 464+ patent application PDFs
Immune Response Patent Applications
Download 464+ Immune Response-related PDFs
For professional research & prior art discovery
inventor
  • 464+ full patent PDF documents of Immune Response-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods and compositions for inhibiting akt3
Augusta University Research Institute, Inc.
July 20, 2017 - N°20170202956

Compounds and compositions for selectively inhibiting akt3 are provided. Methods of using the compounds are also provided. Because akt3 modulates the suppressive function of natural tregs and the polarization of induced tregs, the disclosed compounds are useful for modulating immune responses.
Adjuvanted influenza vaccines for pediatric use
Seqirus Uk Limited
July 20, 2017 - N°20170202955

An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza a ...
Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
Providence Health & Services - Oregon
July 20, 2017 - N°20170202949

Methods are disclosed for producing defective ribosomal products (drips) in blebs (dribbles) by contacting cells with a proteasome inhibitor, and in some examples also an autophagy inducer, thereby producing treated cells. Dribbles can be used to load antigen presenting cells (apcs), thereby allowing the apcs to present the drips and antigenic fragments thereof. Immunogenic compositions that include treated cells, isolated ...
Immune Response Patent Pack
Download 464+ patent application PDFs
Immune Response Patent Applications
Download 464+ Immune Response-related PDFs
For professional research & prior art discovery
inventor
  • 464+ full patent PDF documents of Immune Response-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Anti-mycoplasma spp. subunit vaccine
Agricultural Technology Research Institute
July 20, 2017 - N°20170202942

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp. Subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of mycoplasma spp. In pigs. The vaccine can comprise ...
Ompa and asp14 in vaccine compositions and as diagnostic targets
Virginia Commonwealth University
July 20, 2017 - N°20170202941

Anaplasma phagocytophilum surface proteins asp14 and ompa and homologous genes from anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Asp14 and/or ompa proteins or peptide fragments may be used in combination with other anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to ...
Transgenic algae for delivering antigens to an animal
The Ohio State University
July 20, 2017 - N°20170202940

Delivery systems and methods are provided for delivering a biologically active protein to a host animal. The systems and methods provided include obtaining an algal cell transformed by an expression vector, the expression vector comprising a nucleotide sequence coding for the biologically active protein, operably linked to a promoter. In one illustrated embodiment, the biologically active protein is an antigenic ...
Novel immunotherapy against several tumors, such as lung cancer, including nsclc
Immatics Biotechnologies Gmbh
July 20, 2017 - N°20170202937

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic t cell (ctl) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune ...
An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases
UniversitÉ De Nantes
July 20, 2017 - N°20170202921

The invention relates to an isolated interleukin-34 (il-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of ...
Use of annexin v as a method to block tumor induced immunosuppression of the innate ...
The Board Of Trustees Of The Leland Stanford Junior University
July 20, 2017 - N°20170202914

Methods are provided for treating a subject with cancer, with a therapeutic dose of annexin v to the subject.
Pegylated recombinant bacteriophage
The Board Of Trustees Of The Leland Stanford Junior University
July 20, 2017 - N°20170202891

The present invention provides a recombinantly modified pegylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant. The present invention further provides methods of treatment of mammalian subjects having a bacterial infection by the administration of a pharmaceutically acceptable formulation of a recombinantly modified pegylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant. The present invention further provides pharmaceutically acceptable formulations ...
Immune Response Patent Pack
Download 464+ patent application PDFs
Immune Response Patent Applications
Download 464+ Immune Response-related PDFs
For professional research & prior art discovery
inventor
  • 464+ full patent PDF documents of Immune Response-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Psgl-1 modulators and uses thereof
Sanford-burnham Medical Research Institute
July 13, 2017 - N°20170198047

The present invention relates to the seminal discovery that p-selectin glycoprotein ligand-1 (psgl-1) modulates the immune system and immune responses. Specifically, the present invention provides psgl-1 agonists and antagonists which increase the survival of multifunctional t cells and viral clearance. The present invention further provides methods of treating infectious diseases, cancer and immune and inflammatory diseases and disorders using a ...
Antibody guided vaccines and methods of use for generation of rapid mature immune responses
The Texas A&m University System
July 13, 2017 - N°20170196971

Adjuvant compositions, vaccines, constructs for preparing the adjuvant compositions and vaccines and methods of using the adjuvant compositions and vaccines to enhance immune responses in subjects are provided herein. In particular, a rapid antibody response to the vaccine including both igg (in the circulation) and siga (mucosal secretory iga) is elicited. The adjuvants and vaccines may be used for sub-cutaneous ...
Adjuvant for mucosal vaccine
Osaka University
July 13, 2017 - N°20170196970

An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response in a mucosal membrane. According to the present invention, an adjuvant for a mucosal vaccine containing a protein complex composed of hemagglutinin (ha) subcomponents ha1 and ha2, and mutant subcomponent ha3 of botulinum toxin is provided.
Vaccination in newborns and infants
Curevac Ag
July 13, 2017 - N°20170196969

The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of ...
Microneedle compositions and methods of using same
Verndari, Inc.
July 13, 2017 - N°20170196966

Described herein, are microneedle devices comprising a recombinant alphavirus replicon encoding an exogenous polypeptide, wherein the recombinant alphavirus replicon is coated onto or embedded into a plurality of microneedles. Also described herein are methods of preparing a microneedle device comprising a recombinant alphavirus replicon encoding an exogenous polypeptide. Also disclosed herein are methods of inducing an immune response in an ...
Novel method and compositions
Glaxosmithkline Biologicals, S.a.
July 13, 2017 - N°20170196960

The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the ...
Anti-mycoplasma spp. subunit vaccine
Agricultural Technology Research Institute
July 13, 2017 - N°20170196959

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp. Subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of mycoplasma spp. In pigs. The vaccine can comprise ...
Kif20a epitope peptides for th1 cells and vaccines containing the same
Oncotherapy Science, Inc.
July 13, 2017 - N°20170196956

Isolated kif20a-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to mhc class ii molecules and induce kif20a-specific cytotoxic t lymphocytes (ctls) in addition to th1 cells. Such peptides are ...
Loading